Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Plus Surgery for Relapsed NSCLC
NCT02889666Phase 1Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jan 2008
- Primary completion
- Dec 2026
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Cisplatin micelle injection (HA132), carboplatin, oxaliplatin, docetaxel and gemcitabine in non-small cell lung cancer (NSCLC) (8 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Disease-Free Survival at 5 years. Started Jan 2008; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)carboplatinoxaliplatindocetaxelgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02889666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02889666.